Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy – guidance (TA713)

NICE recommend nivolumab for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if it is PD-L1+ve, and stopped at 2 years of uninterrupted treatment , and they have not had a PD-1 or PD-L1 inhibitor before.

National Institute for Health and Care Excellence